Emerging Therapies for Gastric Cancer

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Gastroenterology & Hepatology".

Deadline for manuscript submissions: 15 June 2026 | Viewed by 1038

Special Issue Editors


E-Mail Website
Guest Editor
1. Centro de Anatomia Patológica Germano de Sousa, Coimbra, Portugal
2. Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal
3. ACIMAGO, Coimbra, Portugal
4. Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Coimbra, Portugal
Interests: animal models of disease; liver transplant pathology; colorectal cancer; liver metastases; GI cancer; surgical pathology; immunohistochemistry; molecular pathology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Surgery Department, Unidade Local de Saude de Coimbra, Coimbra, Portugal
2. Faculdade de Medicina, Universidade de Coimbra, Portugal
3. ACIMAGO, Coimbra, Portugal
4. Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Coimbra, Portugal
Interests: animal models of disease; liver transplant pathology; colorectal cancer; liver metastases; GI cancer; surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Gastric cancer remains one of the most formidable challenges in oncology, characterized by its complex pathophysiology, late-stage diagnosis, and limited treatment options. Despite significant advancements in cancer research, the prognosis for gastric cancer patients continues to be poor, highlighting an urgent need for innovative therapeutic strategies.

This Special Issue, entitled "Emerging Therapies for Gastric Cancer," seeks to address this critical gap by bringing together cutting-edge research and comprehensive reviews from leading scientists and clinicians in the field. We invite contributions that explore novel therapeutic approaches, including targeted therapies, immunotherapies, combination treatments, and advancements in precision medicine tailored specifically for gastric cancer.

This Special Issue aims to illuminate the pathways from bench to bedside, offering insights into the molecular mechanisms driving gastric cancer and the translational research that holds promise for more effective treatments. Original studies that provide new data, as well as review articles that synthesize current knowledge and propose future directions, are both highly encouraged.

Prof. Dr. Rui Caetano Oliveira
Prof. Dr. José Guilherme Tralhão
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastric cancer
  • oncology
  • therapies
  • individualized therapy
  • immunotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 2034 KB  
Review
The Role of FGFR2 as a Novel Biomarker for Treatment of Gastric Cancer—A Literature Review
by João Lages dos Santos, Rui Caetano Oliveira and João Martins Gama
Medicina 2025, 61(11), 1890; https://doi.org/10.3390/medicina61111890 - 22 Oct 2025
Viewed by 490
Abstract
Background: Gastric cancer currently has the third highest mortality rate worldwide among cancer types. Despite gradual declines in mortality rates attributed to improvements in early detection and treatment, outcomes for advanced-stage disease are still poor. The identification of new biomarkers such as fibroblast [...] Read more.
Background: Gastric cancer currently has the third highest mortality rate worldwide among cancer types. Despite gradual declines in mortality rates attributed to improvements in early detection and treatment, outcomes for advanced-stage disease are still poor. The identification of new biomarkers such as fibroblast growth factor receptor 2 (FGFR2) has opened new pathways for directed therapy in gastric cancer. Objective: This review aims to synthesize the current evidence on the role of FGFR2 in gastric cancer, focusing on its biological function and oncogenic mechanisms, diagnostic and prognostic modification, therapeutic targeting, and possible roadblocks in clinical application. Methods: A comprehensive literature search was conducted, selecting studies published between 2015 and 2025 using the MeSH terms “FGFR2 protein, human” [Supplementary Concept]) AND “Stomach Neoplasms”. Articles were screened based on relevance to gastric cancer, language (English), and availability of full text, yielding a final selection of 75 studies, including preclinical research, clinical trials, and reviews. Findings: We compiled and reported the evidence on FGFR2 detection methods, intra-tumoral heterogeneity of FGFR2 expression, effects of FGFR2 expression on prognosis, current therapy options targeting FGFR2, and challenges in pursuing this modality of treatment. Conclusion: FGFR2 represents a promising biomarker and therapeutic target in gastric cancer. Full article
(This article belongs to the Special Issue Emerging Therapies for Gastric Cancer)
Show Figures

Figure 1

Back to TopTop